Gilead granted patent for hepatitis C drug Solvadi
The move is being seen as a possible impact of Indian Prime Minister Narendra Modi’s proposed visit to the US next month
India denies Gilead patent for hepatitis C drug, sofosbuvir
Companies that have not signed any licence agreement with US pharma giant are now free to produce generic versions of the drug
Gilead signs agreements with Indian generic companies for hepatitis C drug
Indian companies granted licence to produce generic sofosbuvir and investigational single tablet regimen of ledipasvir/sofosbuvir for treatment …
After India, China rejects patent claim for hepatitis C drug Sovaldi
Activists claim that the drug was developed using previously published information and an existing compound
World Hepatitis Day: Who can pay for hepatitis C treatment?
Selling price of HCV drugs far higher than production cost, all because of pro-industry patent regime
Maths of Gilead's hepatitis C drug
Why US firm's super expensive drug sofosbuvir costs so much and how it can be made at a tenth of current price
US authority approves more efficacious hepatitis C drug
Sofosbuvir's prohibitive cost will put it out of reach of most patients in developing countries, including India
Patent claim on hepatitis C drug questioned in many countries
With hepatitis C killing at least 700,000 people every year, civil society has strengthened efforts to make the drug accessible